|本期目录/Table of Contents|

[1]李剑瑜,刘鹏年,张霞,等.三七皂苷Rg1对肝纤维化大鼠线粒体质子跨膜 转运的作用机制[J].环球中医药,2015,8(05):523-526.[doi:10.3969/j.issn.16741749.2015.05.003]
　LI Jian yu,LIU Peng nian,ZHANG Xia,et al.Action mechanism of proton translocation across mitochondrial membrane of notoginsenoside Rg1 on hepatic fibrosis rats[J].,2015,8(05):523-526.[doi:10.3969/j.issn.16741749.2015.05.003]
点击复制

三七皂苷Rg1对肝纤维化大鼠线粒体质子跨膜 转运的作用机制()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第8卷
期数:
2015年05期
页码:
523-526
栏目:
论著
出版日期:
2015-05-06

文章信息/Info

Title:
Action mechanism of proton translocation across mitochondrial membrane of notoginsenoside Rg1 on hepatic fibrosis rats
作者:
李剑瑜; 刘鹏年; 张霞; 穆启梅; 高飞; 甄敬辉; 柳伟; 石娜; 武凡
072750河北省涿州市医院输血科
Author(s):
LI Jianyu;  LIU Pengnian;  ZHANG Xia;  et al.
Blood Transfusion Department of Zhuozhou City Hospital, Zhuozhou 072750, China Corresponding author: WU Fan，Email: wufanfan49@163.com
关键词:
肝纤维化; 线粒体; 质子跨膜转运; 膜的流动性; 三七皂苷Rg1
Keywords:
Hepatic fibrosis; Mitochondria; Protontranslocation across mitochondrial membrane; Mitochondrial membrane fluidity; Notoginsenoside Rg1
分类号:
R285
DOI:
10.3969/j.issn.16741749.2015.05.003
文献标志码:
A
摘要:
目的探讨在三七皂苷（panax notoginseng saponins，PnS）Rg1干预下，肝纤维化大鼠线粒体质子跨膜转运的变化和肝线粒体膜的流动性的变化，为开发三七单体Rg1在临床抗纤维化的应用提供详尽的试验依据和理论基础。方法72只Wistar大鼠随机分为对照组、四氯化碳(carbon tetrachloride，CCl4）肝纤维化大鼠模型组、PnS Rg1组各24只。除对照组外，其余2组用5% CCl4橄榄油按5 mL/kg灌胃制作肝纤维化大鼠模型。PnS Rg1组在每次CCl4灌胃同时腹腔注射PnS Rg1（5 mg/kg）用稳态荧光探针标记技术动态观察肝纤维化大鼠线粒体质子跨膜转运的变化，用荧光偏振法测定肝线粒体膜的流动性和膜的微黏度的改变。结果（1）与对照组相比，肝纤维化模型组大鼠用单因素多组间方差分析，发现模型组大鼠质子跨膜转运中，肝线粒体质子跨膜转运能力显著下降（P＜001）。PnS Rg1组与对照组相比质子跨膜转运的变化没有显著性意义（P＞005），与模型组相比，有显著性差异（P＜001）。（2）肝纤维化模型组大鼠用单因素多组间方差分析，与对照组相比，证实模型组大鼠线粒体膜的流动性显著下降（P＜001），增加膜的微黏度（P＜001）；而Rg1组与模型组相比增加线粒体膜的流动性（P＜001），降低膜的微黏度（P＜001）。结论肝纤维化大鼠肝线粒体质子跨膜转运能力下降和线粒体膜的流动性显著下降是导致肝纤维化的重要原因之一。PnS Rg1通过增加肝线粒体质子跨膜转运能力和线粒体膜的流动性而防治肝纤维化的发生发展的。
Abstract:
ObjectiveTo investigate the changes in proton translocation across mitochondrial membrane and hepatic mitochondria membrane fluidity of rats with hepatic fibrosis under the intervention of notoginsenoside Rg1, in order to provide detailed experimental and theoretical basis for the clinical application of notoginsenoside Rg1. Methods72 Wistar rats were randomly divided into control group, carbon tetrachloride (CCl4 ) group, model group and notoginsenoside Rg1 group, and with 24 rats in each group. All the rats received gavage administration with 5% CCl4 solution (5 mL/kg) in addition to the control group, and rats in notoginsenoside Rg1 group received intraperitoneal injection with notoginsenoside Rg1 (5 mg/kg) based on the gavage administration. The change of proton translocation across mitochondrial membrane of rats with hepatic fibrosis was observed dynamically by using steadystate fluorescence probe technique. The change of hepatic mitochondria membrane fluidity and the viscosity of membrane were observed by using fluorescence polarization methods. Results(1)Compared with control group, the ability of protontranslocation across mitochondrial membrane in hepatic was declined significantly of rats in model group (P<001). There was no significant difference in ability of protontranslocation across mitochondrial membrane in hepatic of rats between control and notoginsenoside Rg1 groups (P>005), while the difference was significant between model and notoginsenoside Rg1 groups (P<001).(2)Compared with control group, the mitochondrial membrane fluidity of rats in model group was declined significantly (P<001), and the membrane viscosity was increased significantly (P<001). Compared with model group, the mitochondrial membrane fluidity of rats in notoginsenoside Rg1 group was increased (P<01), while the membrane viscosity was declined significantly (P<001). ConclusionOne of the important causes of hepatic fibrosis rats was the decline in ability of protontranslocation across mitochondrial membrane and membrane fluidity in hepatic. Notoginsenoside Rg1 could prevent the occurrence and development of hepatic fibrosis through increasing the ability of protontranslocation across mitochondrial membrane and membrane fluidity of hepatic.

参考文献/References:

［1］Banasch M，Ellrichmann M，Tannapfel A， et al. The noninvasive (13)Cmethionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in nonalcoholic steatohepatitis [J]. Eur J Med Res，2011，16(6):258264.
[2]武凡，李剑瑜，刘鹏年.三七皂苷Rg1、Rb1抗大鼠肝纤维化的作用及机制研究[J].河北医药，2013，35（18）:27312734.
[3]杨鹤鸣，陆松敏，刘建仓，等.内毒素休克大鼠肝线粒体质子跨膜转运的改变[J].生物化学与生物物理进展，1999，（1）:58.
[4]Parker N，Affourtit C，VidalPuig A，et al. Energizationdependent endogenous activation of proton conductance in skeletal muscle mitochondria[J].Biochem J，2008 ，412(1):131139.
[5]Aoun M，FeilletC，Fouret G，et al.Rat liver mitochondrial membrane characteristics and mitochondrial functions are more profoundly altered by dietary lipid quantity than by dietary lipid quality: effect of different nutritional lipid patterns[J]. Br J Nutr，2012，107（5）： 647659.
[6]Huang P，Li G，Chen C，et al. Differential toxicity of Mn2+ and Mn3+ to rat liver tissues: oxidative damage，membrane fluidity and histopathological changes[J].Exp Toxicol Pathol，2012，64(3):197203.
[7]李剑瑜，张霞，刘鹏年，等.三七皂苷Rg1、Rb1对肝纤维化大鼠线粒体DNA三磷酸腺苷酶6、8亚基的作用机理研究[J].环球中医药，2014，7（8）：591594.
[8]Arduini A，Serviddio G，Escobar J，et al. Mitochondrial biogenesis fails in secondary biliary cirrhosis in rats leading to mitochondrial DNA depletion and deletions[J]. Am J Physiol Gastrointest Liver Physiol，2011，301(1): 119127.
[9]Polyak SJ，Morishima C，Lohmann V，et al. Identification of hepatoprotective flavonolignan from silymarin [J] .Proc Natl Acad Sci USA，2010，107（13）：59955999.

相似文献/References:

[1]徐晨光 闫洁 陈蓝羽 李娟梅 吕文良.丹参有效成分抗肝纤维化作用机制的研究进展[J].环球中医药,2013,6(04):305.
　XU Chen guang,YAN Jie,CHEN Lan yu,et al.Research progress in antihepatic fibrosis mechanism of Salvia Miltiorrhiza[J].,2013,6(05):305.
[2]李川,吕文良.常见中药复方制剂抗肝纤维化机制研究进展[J].环球中医药,2013,6(01):70.
　LI Chuan,LYU Wen liang..Mechanism research of common Chinese patent medicine antifibrotic[J].,2013,6(05):70.
[3]刘文兰 油红捷 车念聪等.一贯煎促进骨髓间充质干细胞逆转肝纤维化的实验研究[J].环球中医药,2014,7(06):401.
　LIU Wen lan,YOU Hong jie,CHE Nian cong,et al.The promotion of Yiguanjian on the recovery of liver fibrosis through mesenchymal stem cells:an experimental study[J].,2014,7(05):401.
[4]王磊,王惠娟,吴凯,等.茵陈蒿汤改善酒精性肝病大鼠肝脏及小肠病变的组织病理学研究[J].环球中医药,2015,8(11):1329.[doi:10.3969/j.issn.1674-1749.2015.11.014]
　WANG Lei,WANG Hui juan,WU Kai,et al.Effect of Yinchenhao decoction on both hepatic and intestinal histopathology in rats with alcoholic liver disease[J].,2015,8(05):1329.[doi:10.3969/j.issn.1674-1749.2015.11.014]
[5]马羽萍 吴超 王裕云 姚海波.芪归四逆散联合恩替卡韦分散片治疗肝郁脾虚血瘀型慢性乙型肝炎肝纤维化48例[J].环球中医药,2016,9(07):862.[doi:10.3969/j.issn.1674-1749.2016.07.031]
[6]郭雨菲,李雪,迟莉.中药单体抗肝纤维化作用研究进展[J].环球中医药,2016,9(09):1149.[doi:10.3969/j.issn.1674-1749.2016.09.040]
　GUO Yu-fei,LI Xue,CHI Li..Research advance on the effect of Chinese medicine monomer on anti-hepatic fibrosis[J].,2016,9(05):1149.[doi:10.3969/j.issn.1674-1749.2016.09.040]
[7]李剑瑜 刘鹏年 张霞等.三七皂甙Rg1、Rb1对肝纤维化大鼠线粒体DNA三磷酸腺苷酶6、8亚基的作用机制研究[J].环球中医药,2014,7(08):591.
　LI Jian-yu,LIU Peng-nian,ZHANG Xia,et al.Study on the mitochondrial mtDNA ATPase6、8 gene mutation and on the function mechanism of panax notoginseng saponins Rg1,Rb1 for hepatic fibrosis rats[J].,2014,7(05):591.

备注/Memo

备注/Memo:
作者单位：072750河北省涿州市医院输血科（李剑瑜、刘鹏年、张霞、穆启梅、甄敬辉、柳伟、石娜），CT室（高飞），检验科（武凡） 作者简介：李剑瑜（1973- ），女，本科，副主任技师。研究方向：临床检验。 Email：ljy1797@163.com 通信作者：武凡（1949- ），女，博士，教授。研究方向：细胞损伤与抗损伤。Email：wufanfan49@163.com
更新日期/Last Update: 1900-01-01